Paliperidone is, almost literally, what your liver turns risperidone into. Specifically, it is 9-hydroxy-risperidone — the major active metabolite of the parent drug. Marketed by Janssen as Invega (oral) and Invega Sustenna / Trinza / Hafyera (long-acting injectable forms with one-, three-, and six-month dosing), paliperidone is functionally the same molecule that risperidone produces inside the body. So why are they marketed and prescribed as different drugs?
Paliperidone and risperidone share a receptor profile and clinical effects, but differ in how they enter the body, how variably they dose between people, and — most importantly in modern practice — the long-acting injectable options available.
The pharmacology
Risperidone is metabolised in the liver primarily by the enzyme CYP2D6 into paliperidone. People vary enormously in CYP2D6 activity — some are "poor metabolisers," others "ultra-rapid metabolisers" — which means the ratio of risperidone to paliperidone in their bloodstream can swing widely. Paliperidone, in contrast, is excreted largely unchanged by the kidneys and bypasses most CYP metabolism. This makes paliperidone's pharmacokinetics more predictable and less affected by drug interactions involving liver enzymes.
At the receptor level, both bind D2 and 5-HT2A receptors with high affinity, plus alpha-1 adrenergic and H1 histamine receptors. Their clinical effects on positive symptoms are very similar.
Clinical efficacy
Head-to-head trials in schizophrenia, summarised in network meta-analyses such as Leucht et al. (Lancet 2013, available via PubMed), show no clinically meaningful efficacy difference between risperidone and paliperidone for positive symptoms or relapse prevention in schizophrenia. Both are middle-of-the-pack atypicals on raw efficacy — less effective than clozapine or olanzapine in the most stringent comparisons, but reliably useful for many patients.
Side effects: more similar than different
Both share the characteristic risperidone-family side-effect profile:
- Hyperprolactinaemia — both raise prolactin substantially, often more than other atypicals; paliperidone may be slightly higher in some studies. This can cause sexual dysfunction, menstrual changes, breast enlargement or discharge, and over time bone density loss. See our prolactin guide.
- Extrapyramidal symptoms — both more dose-dependent than aripiprazole or quetiapine. Risk rises noticeably above 6 mg/day risperidone or its paliperidone equivalent.
- Weight gain and metabolic effects — modest, less than olanzapine but more than aripiprazole or lurasidone.
- Orthostatic hypotension and sedation — both can cause these, especially during titration.
One subtle but real practical difference: because paliperidone is renally cleared, it is more affected by reduced kidney function and may need dose adjustment in older patients or those with renal impairment.
The LAI advantage
For most prescribers and patients in 2026, the most consequential difference is the long-acting injectable lineup. Risperidone has Risperdal Consta (every 2 weeks, requires oral overlap) and the newer Perseris (subcutaneous, monthly). Paliperidone has the most extensive LAI portfolio of any antipsychotic:
- Invega Sustenna — every month
- Invega Trinza — every three months
- Invega Hafyera — every six months
For patients who want minimal dosing intervals, who have struggled with adherence, or whose families and care teams prefer the predictability of an injection, paliperidone's options are unmatched. For maintenance therapy after stabilisation, this is often the deciding factor.
When risperidone is the better choice
- Cost is a concern (oral generic risperidone is one of the cheapest atypicals)
- Dosing flexibility is needed — risperidone's tablet strengths allow finer titration
- Patient is being switched off another oral medication and a familiar oral option is preferred
- CYP2D6 status is not a concern
When paliperidone is the better choice
- Long-acting injectable is the goal, particularly with three- or six-month dosing
- Polypharmacy with strong CYP2D6 inhibitors (e.g., paroxetine, bupropion) creates risperidone dosing concerns
- Liver disease present
- Patient on risperidone is a poor or ultra-rapid metaboliser causing erratic levels
What the evidence does not settle
Direct head-to-head trials of efficacy, prolactin elevation, and weight gain between risperidone and paliperidone are limited, and what exists tends to find clinically small differences. Expert opinion is that the two are largely interchangeable on a pharmacological level — meaning the choice often comes down to dosing form, cost, and prescriber familiarity rather than mechanistic considerations.
If you are on either drug and notice persistent sexual side effects, breast changes, or galactorrhoea, ask your prescriber to check a prolactin level. Both medications are known to elevate it, and the symptoms are addressable.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.